TABLE 4.
Sex-reported Odds ratio (ROR) for commonly reported adverse events with Semaglutide
| PT | a | ROR | ROR (95%Cl) | |
|---|---|---|---|---|
| MEDULLARY THYROID CANCER | 14 | 77.24 | 77.24 (45.02–132.51) | |
| STARVATION KETOACIDOSIS | 4 | 73.65 | 73.65 (26.87–201.9) | |
| ALLODYNIA | 27 | 53.52 | 53.52 (36.4–78.67) | |
| OBSTRUCTIVE PANCREATITIS | 14 | 43.4 | 43.4 (25.47–73.94) | |
| FOOD AVERSION | 35 | 36.73 | 36.73 (26.24–51.41) | |
| POSTPRANDIAL HYPOGLYCAEMIA | 3 | 30.79 | 30.79 (9.79–96.79) | |
| ERUCTATION | 332 | 30.57 | 30.57 (27.4–34.1) | |
| Female | GASTRIC HYPOMOTILITY | 3 | 25.21 | 25.21 (8.04–79.05) |
| THYROID MASS | 54 | 23.1 | 23.1 (17.65–30.24) | |
| DUODENOGASTRIC REFLUX | 3 | 23.04 | 23.04 (7.35–72.19) | |
| BILE ACID MALABSORPTION | 3 | 22.22 | 22.22 (7.1–69.61) | |
| MESENTERIC PANNICULITIS | 4 | 21.59 | 21.59 (8.03–58) | |
| VOMITING PROJECTILE | 35 | 20.48 | 20.48 (14.66–28.61) | |
| GLYCOSYLATED HAEMOGLOBIN DECREASED | 19 | 19.19 | 19.19 (12.2–30.19) | |
| PAPILLARY THYROID CANCER | 21 | 18.9 | 18.9 (12.28–29.08) | |
| PENILE DERMATITIS | 4 | 132.89 | 132.89 (48.58–363.48) | |
| MEDULLARY THYROID CANCER | 9 | 95.39 | 95.39 (49.01–185.68) | |
| MESENTERIC PANNICULITIS | 6 | 64.14 | 64.14 (28.51–144.27) | |
| OBSTRUCTIVE PANCREATITIS | 9 | 54.11 | 54.11 (27.95–104.76) | |
| GASTRIC HYPOMOTILITY | 3 | 49.5 | 49.5 (15.78–155.23) | |
| ALLODYNIA | 13 | 49.49 | 49.49 (28.58–85.72) | |
| ERUCTATION | 204 | 36.6 | 36.6 (31.85–42.05) | |
| Male | FOOD AVERSION | 14 | 28.34 | 28.34 (16.73–48) |
| DIABETIC RETINOPATHY | 30 | 25.75 | 25.75 (17.96–36.9) | |
| NECK MASS | 24 | 24.84 | 24.84 (16.62–37.15) | |
| GLYCOSYLATED HAEMOGLOBIN ABNORMAL | 8 | 24.41 | 24.41 (12.16–48.98) | |
| HICCUPS | 61 | 22.6 | 22.6 (17.55–29.08) | |
| RETINOPATHY | 28 | 21.27 | 21.27 (14.66–30.87) | |
| FLOPPY IRIS SYNDROME | 3 | 21.07 | 21.07 (6.76–65.66) | |
| PANCREATITIS NECROTISING | 16 | 20 | 20 (12.22–32.71) |
Note: a, number of cases with available; PT, preferred term.